Therma Bright Provides Corporate Update on the Saringer and Orpheus Transactions
Toronto, Ontario--(Newsfile Corp. - August 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides this corporate update in response to inquiries from shareholders. Saringer - Asset Acquisition (Benepod® pain relief technology) As previously announced (refer to news releases of January 15, April 8 & July 9, 2020), Therma has completed satisfactory due diligence and intends to acquire Benepod® pain relief technology and...
2020-08-20 5:00 AM EDT
Therma Bright Schließt Die Due-Diligence-Prüfung des COVID-19-Speichelschnelltests CoviSafe(TM) von Orpheus Medica Ab Und Geht in Phase 2 über
Toronto, Ontario--(Newsfile Corp. - Freitag, 14. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, dass es die erste Phase seiner Due Diligence-Prüfung für die Plattformtechnologie von Orpheus Medica ("Orpheus") abgeschlossen hat und die Entwicklung eines Speichelschnelltests (CoviSafe™) zum Nachweis des Virus (SARS-CoV-2), das COVID-19 verursacht, plant. CoviSafe™ wird die neuartigen...
2020-08-14 12:00 AM EDT
Therma Bright Completes Due Diligence of Orpheus Medica's CoviSafe(TM) COVID-19 Rapid Saliva Test and Moves to Phase 2
Toronto, Ontario--(Newsfile Corp. - August 13, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed its Phase 1 due diligence on Orpheus Medica's ("Orpheus") platform technology and plan for the development of a rapid saliva test (CoviSafe™) for the detection of the virus (SARS-CoV-2) causing COVID-19. CoviSafe™ will integrate Orpheus' novel biologics and advanced computational...
2020-08-13 5:00 AM EDT
Therma Bright Announces Closing of Over-Subscribed Private Placement for $1,250,000
Toronto, Ontario--(Newsfile Corp. - August 6, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, announces that it has completed the closing of its non-brokered private placement (the "Offering") previously announced on July 20, 2020 and increased July 22, 2020. The Company has issued 16,666,667 units for gross proceeds of $1,250,000. No finder's fee was paid in conjunction with the Offering. All securities issued are subject...
2020-08-06 4:00 PM EDT
Therma Bright Inc. Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - July 24, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), at the request of IIROC, Therma Bright Inc. wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Therma Bright Inc. Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality...
2020-07-24 3:26 PM EDT
Therma Bright Increases Private Placement to $1,250,000 Due to Increased Demand
Toronto, Ontario--(Newsfile Corp. - July 22, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its news release of July 20, 2020, it has received interest above the previously announced private placement of up to 13,333,334 units at a price of $0.075 per Unit for gross proceeds of up to $1,000,000. Accordingly, the Company intends to increase the amount to be raised under its...
2020-07-22 6:00 AM EDT
Therma Bright Announces up to $1,000,000 Private Placement Financing with Insider Participation and Debt Settlements
Toronto, Ontario--(Newsfile Corp. - July 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it proposes to undertake a non-brokered private placement (the "Private Placement") of up to 13,333,334 units ("Units") at a price of $0.075 per Unit for proceeds of $1,000,000 if the Private Placement is fully subscribed. Each Unit will consist of one common share of the Company and one-half (0.5) of one...
2020-07-20 6:00 AM EDT
Therma Bright Provides Update on Orpheus Medica Rapid Test for COVID-19 Virus in Saliva - CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, is pleased to provide an update on its project with Orpheus Medica to develop a rapid test to detect COVID-19 virus in saliva - the CoviSafeTM. The project will integrate Orpheus' novel biologics platform, coupled with third party rapid detection and portable device technology, to develop a reliable palm-sized test for screening of...
2020-07-16 6:33 AM EDT
Therma Bright Completes Due Diligence to Acquire Medical Device Technology from Saringer Life Science Technologies Inc.
Toronto, Ontario--(Newsfile Corp. - July 9, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed due diligence and will move forward with closing of the asset purchase transaction with Saringer Life Science Technologies Inc. ("Saringer"). As previously reported on January 15, 2020 and April 8th, 2020, the Company entered a non-binding letter of intent ("LOI") to acquire...
2020-07-09 7:15 AM EDT
Therma Bright Enters Into a Binding Letter of Intent with Orpheus Medica to Develop a Rapid Test to Detect COVID-19 Virus in Saliva
Toronto, Ontario--(Newsfile Corp. - July 7, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into a binding letter of intent with Orpheus Medica Inc. ("Orpheus") to partner in the development of a rapid saliva test for the detection of the virus (SARS-CoV-2) causing COVID-19. Therma will provide funding for the project in phases ("Phase" or "Phases") as certain milestones are...
2020-07-07 6:00 AM EDT
Therma Bright Initiates Due Diligence to Manufacture Personal Protective Equipment, Hand Sanitizers and Applies for Government Grants
Toronto, Ontario--(Newsfile Corp. - May 11, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, has initiated due diligence and has applied for government grants to manufacture personal protective equipment ("PPE") and hand sanitizers to combat the Covid-19 crisis. Several potential partners have approached Therma Bright to produce PPE and hand sanitizers for the Canadian and export markets. Therma Bright is ideally...
2020-05-11 4:35 PM EDT
Therma Bright Extends Closing to Acquire Benepod(R) Pain Relief Technology and Other Medical Device Technology from Saringer Life Science Technologies Inc.
Toronto, Ontario--(Newsfile Corp. - April 8, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, has agreed to extend the closing of the asset purchase transaction with Saringer Life Science Technologies Inc. ("Saringer"). As previously reported on January 15, 2020 the Company entered into a non-binding letter of intent ("LOI") to acquire Benepod® pain relief technology and other medical device related technology from...
2020-04-08 9:26 AM EDT
Therma Bright Signs LOI to Acquire Benepod(R) Pain Relief Technology and Other Medical Device Technology from Saringer Life Science Technologies Inc.
Toronto, Ontario--(Newsfile Corp. - January 15, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, enters into a non-binding letter of intent ("LOI") to acquire Benepod® pain relief technology and other medical device related technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). Therma is in the process of conducting due diligence on Saringer. The LOI contemplates that this transaction...
2020-01-15 9:46 AM EST
Therma Bright's International Patent Application for TherOZap(TM) Enters National Phases in the US, Europe & Canada
Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ technology under the Company's former name, The Jenex Corporation, has filed an international patent application under the PCT convention for its thermal therapy TherOZap™ and has recently entered the national phases in the US, Europe and Canada. In the international phase, the international...
2019-09-05 6:30 AM EDT
TherOZap(TM) Technology Test Results Prove Successful at Inhibiting Zika Virus During In-Vitro Tests
Toronto, Ontario--(Newsfile Corp. - September 4, 2019) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ Technology proves successful at inhibiting the Zika virus during in-vitro tests. Therma engaged a top Virology Research Laboratory in Canada to study Therma's TherOZap™ technology's ability to inactivate live Zika virus in culture media and to determine inhibition of the Zika virus infection...
2019-09-04 6:30 AM EDT
Therma Bright Inc. Continues Testing of TherOZap(TM) Technology Against the Zika Virus
Toronto, Ontario--(Newsfile Corp. - July 3, 2019) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its press releases on October 11th and December 17th, 2018 and March 28th, 2019 that the Company continues testing of the TherOZap™ technology against the Zika virus upon the advice of one of the top research laboratories in Canada working with Therma Bright. A number of additional...
2019-07-03 7:00 AM EDT
Therma Bright Inc. in Final Stages of Testing TherOZap(TM) Technology Against the Zika Virus
Toronto, Ontario--(Newsfile Corp. - March 28, 2019) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company is pleased to announce, further to the press releases on October 11th and December 17th, 2018, that the Company is in the final stages of in vitro testing and awaits the results of the TherOZap™ technology against the Zika virus. Testing is being conducted through a top research laboratory in Canada. The Company expects to...
2019-03-28 7:48 AM EDT
Therma Bright Inc. Issues Update on Pain Relief Device and TherOZap(TM) Technology
Toronto, Ontario--(Newsfile Corp. - December 18, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, today announces that it has received the prototype of its pain relief device and provides an update on its TherOZap™ technology. Therma Bright in October introduced the first design of its pain relief product for general, arthritic or orthopedic pain. Rapidly advancing its development, the Company has received the...
2018-12-18 8:30 AM EST
Therma Bright Inc. to Establish Subsidiary for Cannabis Related Devices
Toronto, Ontario--(Newsfile Corp. - November 1, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it will incorporate a 100% wholly owned subsidiary (the "Subsidiary") to hold device related technology for the application or use of medicinal or recreational marijuana. The Company plans to hold the pain relief device, as described in a press release on October 1st, and all related intellectual property...
2018-11-01 8:51 AM EDT
Therma Bright Engages Top Virology Research Group to Conduct Further Tests of TherOZap(TM) Technology Against the Zika Virus
Toronto, Ontario--(Newsfile Corp. - October 11, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company announces, further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology at inhibiting the Zika virus, that the Company has engaged a top research laboratory made up of virology experts to further test the TherOZap™ technology against the Zika virus. The research...
2018-10-11 8:54 AM EDT